News of Note—Preventing cancer spread with a surgical spray; a vaccine against opioid addiction

A spray-on gel could prevent cancer from spreading after surgery, UCLA scientists reported. (Pixabay)

A spray-on gel for reducing cancer metastasis after surgery

Scientists at the University of California, Los Angeles, are developing a gel that surgeons can spray on surgical sites immediately after removing tumors. The idea is to prevent metastasis, which is a leading cause of cancer deaths. The gel is made of calcium-carbonate nanoparticles containing antibodies against the protein CD47, which cancer cells normally use to evade the immune system. It’s designed to promote healing at the tumor site while traveling throughout the body to combat the re-emergence of the cancer. They tried the solution in a mouse model of melanoma and reported that half the animals stayed cancer-free for 60 days after surgery. The research was published in the journal Nature Nanotechnology. (Article)

Preventing opioid addiction with an antibody

Researchers at the Scripps Research Institute have created a vaccine made of monoclonal antibodies that block the pain-relieving effects of the synthetic opioid fentanyl. They believe such a vaccine could be used to prevent opioid addiction and reduce overdose deaths. When they gave the vaccine to mice along with fentanyl and then applied a heated beam of light to their tails, they quickly showed a pain response, whereas animals that weren’t given the vaccine did not withdraw their tails as quickly. When the researchers administered the vaccine along with a dose of fentanyl that would normally be fatal, the mice did not overdose. They presented the research at the American College of Neuropsychopharmacology Annual Meeting. (Release)

How one mutation in a single gene leads to early-onset dementia

Frontotemporal dementia accounts for 20% of cases of the early-onset form of the disease, which can affect people as young as 40. A team led by Washington University School of Medicine has found one mutation in the gene MAPT that they believe causes an inherited form of the disease. Using pluripotent stem cells grown from the skin cells of patients with frontotemporal dementia, the researchers discovered that the MAPT mutation disrupts the ability of neurons to communicate. The mutation is also associated with 61 gene alterations that further disrupt cell signaling, they reported in the journal Translational Psychiatry. They believe the MAPT mutation—as well as some of its downstream genetic impact—could be targeted with drugs. They plan to evaluate whether FDA-approved compounds targeting the genes can prevent memory loss associated with the disease. (Release)


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Suggested Articles

Preclinical studies suggest sGC stimulator IW-6463 can improve dendritic spine density, reduce neuroinflammation and increase brain blood flow.

VISTA represents a novel checkpoint regulator that can be targeted by both agonists and antagonists to trigger opposing therapeutic T-cell effects.

An engineered vaccinia virus carrying two cytokines that stimulate anti-cancer responses prompted tumor regression in mouse models of three cancers.